LCTX
Lineage Cell·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LCTX
Lineage Cell Therapeutics, Inc.
A biotechnology company that develops and commercializes cellular therapies for cancer and immune system disorders
2173 Salk Avenue, Suite 200, Carlsbad, California 92008
A biotechnology company focused on the emerging field of regenerative medicine.
Lineage Cell Therapeutics, Inc., was founded in California in 1990. The company is a clinical-stage biotechnology company developing novel allogeneic or "off-the-shelf" cell therapies to address unmet medical needs. The company's projects are based on the company's proprietary cell-based technology platform and related development and manufacturing capabilities. From this platform, the company designs, develops, manufactures and tests specialized human cells with anatomical and physiological functions similar to or identical to cells naturally found in the human body.
Earnings Call
Q1/2025
Estimate EPS-0.03
Actual EPS-0.02
Estimate Revenue1.72M
Actual Revenue1.50M
Lineage Cell Therapeutics Q1 2025: Unraveling Contradictions in Manufacturing Strategies and FDA Timelines
May 20,2025 10:40
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.03
Actual EPS-0.13
Estimate Revenue1.47M
Actual Revenue2.77M
Lineage Cell Therapeutics: Navigating Key Contradictions in Manufacturing, Trials, and FDA Communication in 2025Q2 Earnings Call
Aug 12,2025 09:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LCTX has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.03, missing expectations. The chart below visualizes how LCTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LCTX has released its 2025 Q3 earnings report, with revenue of 3.68M, reflecting a YoY change of -2.59%, and net profit of -29.75M, showing a YoY change of -891.40%. The Sankey diagram below clearly presents LCTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
